Brean Murray Carret & Co. Maintains a 'Buy' on Medivation (MDVN); Zytiga Data Better Than Expected
Tweet Send to a FriendGet Alerts MDVN Hot Sheet
Price: $48.51 +2.32%
Rating Summary:
18 Buy, 3 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 13 | Down: 25 | New: 24
Rating Summary:
18 Buy, 3 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 13 | Down: 25 | New: 24
Trade MDVN Now!
Brean Murray Carret & Co. maintains a 'Buy' on Medivation (NASDAQ: MDVN) price target of $105.00.
Analyst, Jonathan Ashoff, said, "Johnson & Johnson's (NYSE: JNJ) Zytiga in the pre chemo setting demostrated robust PFS and OS results overall regardless of the patient subgroup analyzed, and had favorable safety profile. The results are beyond anything shown in the provenge trials, and as with the post chemo Zytiga results, we believe that Medivation's enzalutamide will outperform even the Zytiga pre chemo results presented this past weekend."
For an analyst ratings summary and ratings history on Medivation click here. For more ratings news on Medivation click here.
Shares of Medivation closed at $82.68 yesterday, with a 52 week range of $14.32-$89.46.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
Analyst, Jonathan Ashoff, said, "Johnson & Johnson's (NYSE: JNJ) Zytiga in the pre chemo setting demostrated robust PFS and OS results overall regardless of the patient subgroup analyzed, and had favorable safety profile. The results are beyond anything shown in the provenge trials, and as with the post chemo Zytiga results, we believe that Medivation's enzalutamide will outperform even the Zytiga pre chemo results presented this past weekend."
For an analyst ratings summary and ratings history on Medivation click here. For more ratings news on Medivation click here.
Shares of Medivation closed at $82.68 yesterday, with a 52 week range of $14.32-$89.46.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- UPDATE: UBS Downgrades Carnival (CCL) to Neutral; Worst May Not Be Behind
- Microsoft (MSFT) Rally Not Over Says UBS; Raises PT to $40
- UPDATE: Michael Kors (KORS) Under-Appreciated; Canaccord Genuity Starts at Buy
Create E-mail Alert Related Categories
Analyst CommentsRelated Entities
Brean Murray Carret & Co.
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
